Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tevogen Bio Holdings Inc (TVGN)

Tevogen Bio Holdings Inc (TVGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 17,367
  • Shares Outstanding, K 4,048
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,730 K
  • EBIT $ -31 M
  • EBITDA $ -30 M
  • 60-Month Beta -0.76
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.14 +6.40%
on 03/30/26
13.20 -66.68%
on 03/02/26
-8.81 (-66.69%)
since 02/27/26
3-Month
4.14 +6.40%
on 03/30/26
20.85 -78.90%
on 01/09/26
-14.64 (-76.88%)
since 12/26/25
52-Week
4.14 +6.40%
on 03/30/26
75.50 -94.17%
on 06/06/25
-55.60 (-92.67%)
since 03/28/25

Most Recent Stories

More News
Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen’s position in oncology, rare diseases, and medical devices Target CRO operates...

TVGNW : 0.0339 (+7.96%)
TVGN : 4.40 (+2.56%)
Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement

WARREN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) received written notice (the “Notification Letter”) from The Nasdaq...

TVGNW : 0.0339 (+7.96%)
TVGN : 4.40 (+2.56%)
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)

WARREN, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced that Mittul Mehta, Chief Information Officer and Head of...

TVGNW : 0.0339 (+7.96%)
TVGN : 4.40 (+2.56%)
Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

Lead investor confirmed his intention to maintain his current shareholdings. Company does not anticipate using more than 1% of our authorized shares, including placement through the ATM, over the next...

TVGNW : 0.0339 (+7.96%)
TVGN : 4.40 (+2.56%)
Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure

WARREN, N.J., March 13, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced performance advancements for its artificial intelligence...

TVGNW : 0.0339 (+7.96%)
TVGN : 4.40 (+2.56%)
Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform

WARREN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today issued a statement from Founder and CEO Dr. Ryan Saadi regarding the...

TVGNW : 0.0339 (+7.96%)
TVGN : 4.40 (+2.56%)
Tevogen Names Leadership Team to Execute Diversified Growth Strategy

WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced the appointment of interim leaders across its core business...

TVGNW : 0.0339 (+7.96%)
TVGN : 4.40 (+2.56%)
Letter to Shareholders from CEO Dr. Ryan Saadi

WARREN, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ). Dear Shareholders, As we continue executing on Tevogen’s long-term...

TVGNW : 0.0339 (+7.96%)
TVGN : 4.40 (+2.56%)
Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical

WARREN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced that it has entered into a signed, non-exclusive, non-binding...

TVGNW : 0.0339 (+7.96%)
TVGN : 4.40 (+2.56%)
Tevogen Announces Reverse Stock Split

WARREN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced that its Board of Directors (the “Board”) has approved...

TVGNW : 0.0339 (+7.96%)
TVGN : 4.40 (+2.56%)

Business Summary

Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers. Tevogen Bio Holdings Inc., formerly known as SEMPER PAR ACQ, is based in Warren, New Jersey.

See More

Key Turning Points

3rd Resistance Point 4.91
2nd Resistance Point 4.73
1st Resistance Point 4.51
Last Price 4.40
1st Support Level 4.10
2nd Support Level 3.92
3rd Support Level 3.70

See More

52-Week High 75.50
Fibonacci 61.8% 48.24
Fibonacci 50% 39.82
Fibonacci 38.2% 31.40
Last Price 4.40
52-Week Low 4.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.